CamilleLuciaBedrosianMD

PubMed

• 1 citations
  Clinical trial data available for UX001, aceneuramic acid extended-release
  Camille L. Bedrosian> ;Journal of the Neurological Sciences. 2020 Apr 15
• 54 citations
  Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200
  Daruka Mahadevan, Mark C. Lanasa, Charles M. Farber, Manjari Pandey, Maria Whelden, Susan J. Faas, Terrie L Ulery, Anjli Kukreja, Lan Li, Camille L. Bedrosian, Xiaopin...> ;Journal for Immunotherapy of Cancer. 2019 Aug 23
• 127 citations
  Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis
  Gérard Socié, Marie-Pierre Caby-Tosi, Jing L. Marantz, Alexander Cole, Camille L. Bedrosian, Christoph Gasteyger, Arshad Mujeebuddin, Peter Hillmen, Johan Vande Walle,...> ;British Journal of Haematology. 2019 Apr 1
• 19 citations
  Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry
  Antonio Almeida, Camille L. Bedrosian, Alexander Cole, Petra Muus, Hubert Schrezenmeier, Jeff Szer, Wendell F. Rosse> ;Internal Medicine Journal. 2017 Sep 1
• 207 citations
  Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial
  Fadi Fakhouri, Maryvonne Hourmant, Josep M. Campistol, Spero R. Cataland, Mario Espinosa, A. Osama Gaber, Jan Menne, Enrico Eugenio Minetti, François Provôt, Eric Rond...> ;American Journal of Kidney Diseases. 2016 Jul 1
• 189 citations
  Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
  Larry A. Greenbaum, Marc Fila, Gianluigi Ardissino, Samhar I. Al-Akash, Jonathan R. Evans, Paul Henning, Kenneth Lieberman, Silvio Maringhini, Lars Pape, Lesley Rees, ...> ;Kidney International. 2016 Mar 1
• 13 citations
  Assessment of Human Antihuman Antibodies to Eculizumab After Long‐Term Treatment in Patients With Paroxysmal Nocturnal Hemoglobinuria
  Peter Hillmen, Petra Muus, Jeff Szer, Anita J. Hill, Britta Höchsmann, Austin G. Kulasekararaj, Antonio M. Risitano, Eric Van Den Neste, Maria Liljeholm, Kurt S. Ebrah...> ;American Journal of Hematology. 2016 Mar 1
• 138 citations
  Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS.
  Roxanne Cofiell, Anjli Kukreja, Krystin Bedard, Yan Yan, Angela P. Mickle, Masayo Ogawa, Camille L. Bedrosian, Susan J. Faas> ;Blood. 2015 May 21
• 281 citations
  Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies
  Christoph Licht, Larry A. Greenbaum, Petra Muus, Sunil Babu, Camille L. Bedrosian, David J. Cohen, Yahsou Delmas, Kenneth W. Douglas, Richard R. Furman, Osama Gaber, T...> ;Kidney International. 2015 May 1
• 28 citations
  Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria.
  Ulrike M. Reiss, Jeffrey L. Schwartz, Kathleen M. Sakamoto, Geetha Puthenveetil, Masayo Ogawa, Camille L. Bedrosian, Russell E. Ware> ;Pediatric Blood & Cancer. 2014 Sep 1
• 23 citations
  Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial.
  Yuzuru Kanakura, Kazuma Ohyashiki, Tsutomu Shichishima, Shinichiro Okamoto, Kiyoshi Ando, Haruhiko Ninomiya, Tatsuya Kawaguchi, Shinji Nakao, Hideki Nakakuma, Junichi ...> ;International Journal of Hematology. 2013 Aug 11
• 14 citations
  Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial
  Lori Berk, Monica M. Mita, Jeff Kreisberg, Camille L. Bedrosian, Anthony W. Tolcher, Tim Clackson, Victor M. Rivera> ;Cancer Chemotherapy and Pharmacology. 2012 Jan 10
• 43 citations
  Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria : the AEGIS Clinical Trial
  Yuzuru Kanakura, Kazuma Ohyashiki, Tsutomu Shichishima, Shinichiro Okamoto, Kiyoshi Ando, Haruhiko Ninomiya, Tatsuya Kawaguchi, Shinji Nakao, Hideki Nakakuma, Junichi ...> ;International Journal of Hematology. 2011 Jan 12
• 77 citations
  A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies
  Christine Hartford, Apurva A. Desai, Linda Janisch, Theodore Karrison, Victor M. Rivera, Lori Berk, John W. Loewy, Hedy L. Kindler, Walter M. Stadler, H. L. Knowles, C...> ;Clinical Cancer Research. 2009 Feb 15
• Pharmacokinetics of oral deforolimus (AP23573, MK-8669).
  Fetterly GJ, Mita MM, Britten CD, Poplin E, Tap WD, Carmona A, Yonemoto L, Bedrosian CL, Rubin EH, Tolcher AW> ;J. Clin. Oncol.. 2008-05-20
• Deforolimus trial 106- A Phase I trial evaluating 7 regimens of oral Deforolimus (AP23573, MK-8669).
  Mita MM, Britten CD, Poplin E, Tap WD, Carmona A, Yonemoto L, Wages DS, Bedrosian CL, Rubin EH, Tolcher AW> ;J. Clin. Oncol.. 2008-05-20
• 179 citations
  A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malign...
  David A. Rizzieri, Eric J. Feldman, John F. DiPersio, Nashat Gabrail, Wendy Stock, Roger Strair, Victor M. Rivera, Maher Albitar, Camille L. Bedrosian, Francis J. Giles> ;Clinical Cancer Research. 2008 May 1
• 218 citations
  Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients...
  Monica M. Mita, Alain C. Mita, Quincy Chu, Eric K. Rowinsky, Gerald J. Fetterly, M. Goldston, Amita Patnaik, Lesley Mathews, A. Ricart, Theresa Mays, H. L. Knowles, Vi...> ;Journal of Clinical Oncology. 2008 Jan 20
• Development of a pharmacokinetic (PK) model and assessment of patient (pt) covariate effects on dose-dependent PK following different dosing schedules in two phase I t...
  Desai AA, Mita M, Fetterly GJ, Chang C, Netsch M, Knowles HL, Bedrosian CL, Rowinsky E, Tolcher AW, Ratain MJ> ;J. Clin. Oncol.. 2005-06-01
• Pharmacodynamic study of skin biopsy specimens in patients (pts) with refractory or advanced malignancies following administration of AP23573, an mTOR inhibitor.
  Rivera VM, Kreisberg JI, Mita MM, Goldston M, Knowles HL, Herson J, Rowinksy E, Bedrosian CL, Tolcher A> ;J. Clin. Oncol.. 2005-06-01
• Early response evaluation of therapy with AP23573 (an mTOR inhibitor) in sarcoma using [18F]2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) scan.
  Sankhala KK, Chawla SP, Iagaru A, Dellamaggiora R, Chua V, Daly S, Bedrosian CL, Edwards GK, Cohen S, Demetri GD> ;J. Clin. Oncol.. 2005-06-01
• A phase II study of AP23573 (an mTOR inhibitor) in patients (pts) with advanced sarcomas.
  Chawla SP, Sankhala KK, Chua V, Menendez LR, Eilber FC, Eckardt JJ, Daly ST, Rana GS, Bedrosian CL, Demetri GD> ;J. Clin. Oncol.. 2005-06-01
• A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies.
  Feldman E, Giles F, Roboz G, Yee K, Curcio T, Rivera VM, Albitar M, Laliberte R, Bedrosian CL> ;J. Clin. Oncol.. 2005-06-01
• PTEN expression in archival tumor samples in patients (pts) with advanced malignancies in two phase I studies of AP23573 (AP), an mTOR inhibitor.
  Janisch LA, Desai AA, Mita M, Parsons R, Goldston M, Knowles HL, Bedrosian CL, Rowinsky EK, Tolcher AW, Ratain MJ> ;J. Clin. Oncol.. 2005-06-01
• A phase I trial of a novel mTOR inhibitor AP23573 administered weekly (wkly) in patients (pts) with refractory or advanced malignancies: A pharmacokinetic (PK) and pha...
  Desai AA, Janisch L, Berk LR, Knowles HL, Rivera VM, Bedrosian CL, Ratain MJ> ;J. Clin. Oncol.. 2004-07-15
• Join now to see all